iRhythm (IRTC) Q3 2026 Earnings Call Transcript

iRhythm reported Q3 revenue of $221.6 million, up 14.9% year over year, and adjusted EBITDA margin of 23.1%, up 1,190 basis points; it raised 2026 revenue guidance to $890 million–$895 million and adjusted EBITDA margin guidance to 15.5%–16.0%. Management targets approximately $1 billion in 2027 organic revenue and at least 15% adjusted EBITDA margin, while expecting more than $100 million in cumulative savings over five years from its third-generation AI algorithm. Offsetting factors include flat Zio AT revenue amid customer onboarding delays, a planned Zio MCT FDA submission pushed to 2027, and a $50 million IP settlement charge included in the GAAP net loss of $29.9 million.

Analysis

IRTC’s key near-term risk is not underlying Zio Monitor demand; it is a workflow bottleneck created by selling an expanded portfolio before customers can access it through one integrated platform. Deferred onboarding creates a second-order risk: accounts may use the pause to deepen incumbent-provider relationships, so delayed revenue is not automatically recaptured. Conversely, if EHR integration works, IRTС can use its larger sales channel to cross-sell VitalConnect into existing accounts—but payer coverage, inventory and implementation capacity, rather than addressable market size, will constrain the ramp.

The MCT portfolio is complementary, but the lack of meaningful pricing leverage under common reimbursement codes makes execution and volume the main value drivers. Zio AT weakness and the delayed Zio MCT filing leave less margin for integration slippage. The Q3 adjusted margin is also a poor run-rate anchor: tariff refunds boosted gross margin, while management’s 2027 margin floor signals investment will absorb some operating leverage. Treat the projected AI savings as unverified until reflected in reported costs.

Over the next 1–3 months, watch customer onboarding and the planned Q1 2027 single-platform availability; over 6–18 months, watch VitalConnect growth, payer access, and FDA progress. FDA follow-up inspection and ongoing DOJ discussions are additional execution risks. The constructive thesis is falsified by continued AT/onboarding weakness after integration, VitalConnect growth below the company’s organic rate, or a reduction to 2027 organic revenue or margin expectations.

Key Decisions for Investors

• No immediate earnings-chase trade: treat IRTC as a catalyst watch until the combined platform is broadly available. Consider adding only after evidence of onboarding recovery, not on management’s integration timeline alone.
• Track quarterly new-account volume, AT revenue, and VitalConnect growth separately. A rebound in new accounts after integration supports the cross-sell thesis; continued deferrals or weak VitalConnect growth argues against adding.
• Do not capitalize the full $100 million AI-savings projection into forward margins yet. Reassess when savings appear in operating costs alongside maintained growth investment and the 2027 margin outlook.
• Falsification triggers: a downward revision to the approximately $1 billion 2027 organic revenue trajectory or the 15% adjusted EBITDA margin floor; material slippage in platform integration; or adverse FDA inspection/regulatory developments.